IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors
IQVIA Holdings Inc. closed 22.27% below its 52-week high of $261.73, which the company achieved on March 8th.
Truist Financial Keeps Their Buy Rating on IQVIA Holdings (IQV)
In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on IQVIA Holdings (IQV – Research Report). The
Is IQVIA Holdings (NYSE:IQV) A Risky Investment?
As you can see below, IQVIA Holdings had US$13.6b of debt, at September 2024, which is about the same as the year before. You can click the chart for greater detail. However, because it has a cash reserve of US$1.71b, its net debt is less, at about US$11.9b.
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors
Shares of IQVIA Holdings Inc. IQV slipped 1.12% to $199.11 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and Dow Jones Industrial Average DJIA falling 0.28% to 44,421.91.
Here's Why IQVIA Holdings (IQV) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank,
IQVIA Holdings (IQV) Gets a Buy from Barclays
Barclays analyst Luke Sergott maintained a Buy rating on IQVIA Holdings (IQV – Research Report) today and set a price target of $235.00. The
IQVIA's SWOT analysis: data-driven leader faces headwinds in evolving healthcare market
IQVIA Holdings Inc. (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services for the healthcare and life sciences industries, finds itself at a critical ...
IQVIA Holdings Insiders Sell US$5.3m Of Stock, Possibly Signalling Caution
Over the past year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a significant stake in the company which ...
Iqvia price target lowered to $235 from $255 at Barclays
Barclays lowered the firm’s price target on Iqvia (IQV) to $235 from $255 and keeps an Overweight rating on the shares. The firm says the life ...
ENDPOINTS NEWS1d
US biosim­i­lar 'void' spells trou­ble as bi­o­log­ic patent ex­pi­ra­tions loom, IQVIA re­port says
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for ...
IQVIA named to the Fortune® World’s Most Admired Companies™ list, ranked No. 1 in its sector for fourth consecutive year
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, ...
Seeking Alpha5d
IQV IQVIA Holdings Inc.
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia ...
psychiatryadvisor.com1d
Stimulant Dispensing to Children Decreased After Start of Pandemic, During Shortage
(HealthDay News) — Stimulant dispensing to children aged 5 to 17 years decreased after the start of the COVID-19 pandemic and during a shortage of immediate-release mixed amphetamine salts in October ...
Iqvia downgraded to Neutral from Buy at BTIG
BTIG analyst David Larsen downgraded Iqvia (IQV) to Neutral from Buy without a price target The firm says clinical research organization ...